Description

SK-OV-3 is a human ovarian cancer cell line with epithelial-like morphology. These cells are resistant to tumor necrosis factor and to other cytotoxic drugs such as diphtheria toxin, cisplatin, and adriamycin. The SK-OV-3 cell line forms colonies in soft agar, which serves as a surrogate assay for tumorigenicity. Intra-peritoneal injection of these cells into immunocompromised mice results in the growth of tumors resembling clear cell adenocarcinoma, within two to three months.

Source

This cell line was established in 1973 from the ascites of a 64-year-old Caucasian female with adenocarcinoma of the ovary.

Inventors

• Lloyd J. Old, MD, former William E. Snee Chair in Cancer Immunology, Memorial Sloan Kettering; former Director, New York Branch, Ludwig Institute for Cancer Research
• Germain Trempe, formerly at Sloan Kettering Institute, Memorial Sloan Kettering

Key References

• Fogh J et al. (1977) One hundred and twenty-seven cultured human tumor cell lines producing tumors in nude mice. Journal of the National Cancer Institute 59: 221-226 (PubMed ID: 327080)
• Shaw TJ et al. (2004) Characterization of intraperitoneal, orthotopic, and metastatic xenograft models of human ovarian cancer. Molecular Therapy 10: 1032–1042 (PubMed ID: 15564135)

Licensing Information

This cell line may be licensed nonexclusively for research or commercial purposes.

• Express License:  For internal research purposes by a for-profit entity:  1) Fill out MSK’s ATCC Express License, see here for links to the online fillable ATCC Express License, as well as a PDF version.  2) After execution by MSK, you will receive a signed copy, and can then place your order with ATCC. For detailed guidance on how to fill out this webform, see here. Please note:  In order to streamline and expedite the licensing of select MSK cell lines, the terms of this non-exclusive license are non-negotiable. This license is only available for select cell lines, including this one. Once this license has been executed by MSK, you will receive a signed copy and payment instructions; all payments up to $10,000 must be made by credit card.
• Commercial License: Contact MSK’s Tangible Materials team at [email protected].

For non-licensing requests from academic-research institutions: Contact Frances Weis-Garcia, PhD, Associate Laboratory Member/Head, Antibody & Bioresource Core Facility, MSK, 646-888-2354, [email protected].